blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3088522

EP3088522 - METHODS AND COMPOSITIONS RELATED TO MUTANT KUNITZ DOMAIN I OF TFPI-2 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.10.2018
Database last updated on 04.06.2024
FormerThe patent has been granted
Status updated on  27.10.2017
FormerGrant of patent is intended
Status updated on  15.06.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200 / US
[2016/44]
Inventor(s)01 / BAJAJ, Paul, S.
704 West Holme Ave.
Los Angeles, CA 90024 / US
 [2016/44]
Representative(s)Leißler-Gerstl, Gabriele
Hoefer & Partner
Patentanwälte mbB
Pilgersheimer Strasse 20
81543 München / DE
[2017/48]
Former [2016/44]Leissler-Gerstl, Gabriele
Hoefer & Partner
Patentanwälte
Pilgersheimer Strasse 20
81543 München / DE
Application number, filing date16160326.129.12.2006
[2016/44]
Priority number, dateUS20050754731P29.12.2005         Original published format: US 754731 P
[2016/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3088522
Date:02.11.2016
Language:EN
[2016/44]
Type: B1 Patent specification 
No.:EP3088522
Date:29.11.2017
Language:EN
[2017/48]
Search report(s)(Supplementary) European search report - dispatched on:EP28.07.2016
ClassificationIPC:C12N15/09, C12P21/06, C12N15/00, A61K38/48, A61K38/00, C07K4/00, C07K14/81, A61K48/00
[2016/44]
CPC:
C07K14/8114 (EP,US); A61P17/02 (EP); A61P19/00 (EP);
A61P19/02 (EP); A61P19/08 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P41/00 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P7/04 (EP); A61P9/00 (EP);
A61P9/10 (EP); A01K2217/05 (EP,US); A01K2227/105 (EP,US);
A01K2267/0375 (EP,US); A61K48/00 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/23]
Former [2016/44]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN IN VERBINDUNG MIT MUTANTER KUNITZ-DOMÄNE I VON TFPI-2[2016/44]
English:METHODS AND COMPOSITIONS RELATED TO MUTANT KUNITZ DOMAIN I OF TFPI-2[2016/44]
French:METHODES ET COMPOSITIONS ASSOCIEES AU DOMAINE KUNITZ MUTANT I DE TFPI-2[2016/44]
Examination procedure15.03.2016Date on which the examining division has become responsible
02.05.2017Amendment by applicant (claims and/or description)
02.05.2017Examination requested  [2017/23]
14.06.2017Communication of intention to grant the patent
23.10.2017Fee for grant paid
23.10.2017Fee for publishing/printing paid
23.10.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06848474.0  / EP1976985
EP13157687.8  / EP2653542
Opposition(s)30.08.2018No opposition filed within time limit [2018/45]
Fees paidRenewal fee
12.07.2016Renewal fee patent year 03
12.07.2016Renewal fee patent year 04
12.07.2016Renewal fee patent year 05
12.07.2016Renewal fee patent year 06
12.07.2016Renewal fee patent year 07
12.07.2016Renewal fee patent year 08
12.07.2016Renewal fee patent year 09
31.03.2016Renewal fee patent year 10
27.12.2016Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.12.2006
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
TR29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
BG28.02.2018
GR01.03.2018
IS29.03.2018
[2020/33]
Former [2020/28]HU29.12.2006
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
TR29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
BG28.02.2018
GR01.03.2018
Former [2020/16]HU29.12.2006
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
TR29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
BG28.02.2018
GR01.03.2018
Former [2019/31]HU29.12.2006
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
BG28.02.2018
GR01.03.2018
Former [2019/30]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
BG28.02.2018
GR01.03.2018
Former [2018/52]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
BG28.02.2018
GR01.03.2018
Former [2018/50]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SK29.11.2017
IE29.12.2017
LU29.12.2017
BE31.12.2017
BG28.02.2018
GR01.03.2018
Former [2018/45]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SK29.11.2017
IE29.12.2017
LU29.12.2017
BG28.02.2018
GR01.03.2018
Former [2018/43]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SK29.11.2017
LU29.12.2017
BG28.02.2018
GR01.03.2018
Former [2018/42]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
SE29.11.2017
SK29.11.2017
BG28.02.2018
GR01.03.2018
Former [2018/37]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
SE29.11.2017
SK29.11.2017
BG28.02.2018
GR01.03.2018
Former [2018/35]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
SE29.11.2017
SK29.11.2017
BG28.02.2018
GR01.03.2018
Former [2018/34]AT29.11.2017
DK29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
SE29.11.2017
BG28.02.2018
GR01.03.2018
Former [2018/24]AT29.11.2017
FI29.11.2017
LT29.11.2017
LV29.11.2017
SE29.11.2017
BG28.02.2018
GR01.03.2018
Former [2018/22]FI29.11.2017
LT29.11.2017
Documents cited:Search[A]WO9518830  (PROTEIN ENG CORP [US], et al) [A] 1-14 * abstract * * page 4, line 32 - page 5, line 12 * * page 29; table 2 * * page 30; table 3 * * page 31 - page 36; table 4 *;
 [A]WO9314120  (NOVO NORDISK AS [DK]) [A] 1-14 * abstract * * page 3, line 36 - page 4, line 26 * * page 6, line 6 - line 10 * * page 7, line 14 - line 17 *;
 [A]  - MINAGAWA SONOMI ET AL, "Isolation and amino acid sequences of two Kunitz-type protease inhibitors from the sea anemone Anthopleura aff. xanthogrammica", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B, (199710), vol. 118, no. 2, ISSN 0305-0491, pages 381 - 386, XP002519998 [A] 1-14 * abstract * * page 384; figure 4 *

DOI:   http://dx.doi.org/10.1016/S0305-0491(97)00174-0
by applicantUS7070969
 US3610795
 US4609725
 US4595674
 EP0045665
    - MANAGO ET AL., N ENGL J MED, (2006), vol. 354, pages 353 - 65
    - PATHOPL1YSIOL HAEMOST THROMB., (2005), vol. 34, no. 4-5, pages 188 - 93
    - WATSON ET AL., Molecular Biology of the Gene, PUBLISHING COMPANY, INC., (1987), vol. I, II
    - ANN NY ACAD SCI, (1949), vol. 51, pages 660 - 669
    - SENTER ET AL., BIOCONJUGATE CHEM., (1991), vol. 2, pages 447 - 451
    - BAGSHAWE, K.D., BR. J. CANCER, (1989), vol. 60, pages 275 - 281
    - BAGSHAWE ET AL., BR. J. CANCER, (1988), vol. 58, pages 700 - 703
    - SENTER ET AL., BIOCONJUGATE CHERN., (1993), vol. 4, pages 3 - 9
    - BATTELLI ET AL., CANCER IMMUNOL. IMMUNOTHER., (1992), vol. 35, pages 421 - 425
    - PIETERSZ; MCKENZIE, IMMUNOLOG. REVIEWS, (1992), vol. 129, pages 57 - 80
    - ROFFLER ET AL., BIOCHEM. PHARMACOL, (1991), vol. 42, pages 2062 - 2065
    - HUGHES ET AL., CANCER RESEARCH, (1989), vol. 49, pages 6214 - 6220
    - LITZINGER; HUANG, BIOCHIMICA ET BIOPHYSICA ACTA, (1992), vol. 1104, pages 179 - 187
    - BROWN; GREENE, DNA AND CELL BIOLOGY, vol. 10, no. 6, pages 399 - 409
    - GUTKOWSKA ET AL., ENDOCRINOLOGY AND METABOLISM CLINICS OF AMERICA, (1987), vol. 16, no. 1, page 183
    - MERRIFIELD, J AMER CHEM SOC, (1963), vol. 85, pages 2149 - 2154
    - MERRIFIELD, SCIENCE, (1986), vol. 232, pages 341 - 347
    - WADE ET AL., BIOPOLYMERS, (1986), vol. 25, pages S21 - S37
    - FIELDS, INTJ POLYPEPTIDE PROT RES, (1990), vol. 35, page 161
    - TAN; KAISER, BIOCHEMISTRY, (1977), vol. 16, pages 1531 - 41
    - ATHERTON ET AL., J CHEM SOC PERKIN TRANS, (1981), vol. 1, pages 538 - 546
    - SHEPPARD ET AL., INT J POLYPEPTIDE PROT RES, (1982), vol. 20, pages 451 - 454
    - SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
    - NEEDLEMAN; WUNSCH, J. MOL BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, page 2444
    - ZUKER, M., SCIENCE, (1989), vol. 244, pages 48 - 52
    - JAEGER ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 7706 - 7710
    - JAEGER ET AL., METHODS ENZYMOL., (1989), vol. 183, pages 281 - 306
    - LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 6553 - 6556
    - PASTAN ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, page 4486
    - MILLER ET AL., MOL. CELL. BIOL., (1986), vol. 6, page 2895
    - MITANI ET AL., HUM. GENE THER., (1994), vol. 5, pages 941 - 948
    - GOODMAN ET AL., BLOOD, (1994), vol. 84, pages 1492 - 1500
    - NAIDINI ET AL., SCIENCE, (1996), vol. 272, pages 263 - 267
    - AGRAWAL ET AL., EXPER. HEMATOL., (1996), vol. 24, pages 738 - 747
    - SCHWARTZENBERGER ET AL., BLOOD, (1996), vol. 87, pages 472 - 478
    - CRYSTAL, HUM. GENE THER., (1997), vol. 8, pages 985 - 1001
    - ALVAREZ; CURIEL, HUM. GENE THER., (1997), vol. 8, pages 597 - 613
    - T.E. CREIGHTON, Proteins: Structure and Molecular Properties, W. H. FREEMAN & CO., (1983), pages 79 - 86
    - THORSON ET AL., METHODS IN MOLEC. BIOL., (1991), vol. 77, pages 43 - 73
    - ZOLLER, CURRENT OPINION IN BIOTECHNOLOGY, (1992), vol. 3, pages 348 - 354
    - IBBA, BIOTECHNOLOGY & GENETIC ENGINERRING REVIEWS, (1995), vol. 13, pages 197 - 216
    - CAHILL ET AL., TIBS, (1989), vol. 14, no. 10, pages 400 - 403
    - BENNER, TIB TECH, (1994), vol. 12, pages 158 - 163
    - IBBA; HENNECKE, BIO/TECHNOLOGY, (1994), vol. 12, pages 678 - 682
    - SPATOLA, A. F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, MARCEL DEKKER, (1983), page 267
    - SPATOLA, A. F., "Peptide Backbone Modifications (general review", VEGA DATA, (198303), vol. 1, no. 3
    - MORLEY, TRENDS PHARM SCI, (1980), pages 463 - 468
    - HUDSON, D. ET AL., INT J PEPT PROT RES, (1979), vol. 14, pages 177 - 185
    - SPATOLA ET AL., LIFE SCI, (1986), vol. 38, pages 1243 - 1249
    - HANN J., CHEM SOC PERKIN TRANS., (1982), pages 1307 - 314
    - ALMQUIST ET AL., J. MED. CHERN., (1980), vol. 23, pages 1392 - 1398
    - JENNINGS-WHITE ET AL., TETRAHEDRON LETT, (1982), vol. 23, page 2533
    - CA, (1982), vol. 97, page 39405
    - HOLLADAY ET AL., TETRAHEDRON. LETT, (1983), vol. 24, pages 4401 - 4404
    - HRUBY, LIFE SCI, (1982), vol. 31, pages 189 - 199
    - RIZO; GIERASCH, ANN. REV. BIOCHEM., (1992), vol. 61, page 387
    - PETERSEN ET AL., BIOCHEMISTRY, (19960109), vol. 35, no. 1, pages 266 - 272
    - MASCI ET AL., BLOOD COAGULATION AND FIBRINOLYSIS, (2000), vol. 11, no. 4, pages 385 - 393
    - MASCI ET AL., BLOOD COAGULATION AND FIBRINOLYSIS, (2000), vol. 11, pages 385 - 393
    - GANS H; CASTANEDA AR; SUBRAMANIAN V; JOHN S; LILLEHEI CW, "Problems in hemostasis during open heart surgery. IX. Changes observed in the plasminogen-plasmin system and their significance for therapy", ANN SURG, (1967), vol. 166, pages 980 - 986
    - SHAHIAN DM; LEVINE JD., "Open-heart surgery in a patient with heterozygous alpha 2-antiplasmin deficiency. Perioperative strategies in the first reported case", CHEST, (1990), vol. 97, pages 1488 - 1490
    - TAGGART DP; DIAPARDY V; NAIK M; DAVIES A., "A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting", JTHORAC CARDIOVASC SURG, (2003), vol. 126, pages 1087 - 94
    - SIEVERT A; MCCALL M; BLACKWELL M; BRADLEY S., "Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery", ANADOLU KARDIYOL DERG., (2005), vol. 5, pages 36 - 40
    - KOKOSZKA A; KUFLIK P; BITAN F; CASDEN A; NEUWIRTH M., "Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery", JBONE JOINT SURG AM, (2005), vol. 87, pages 1129 - 36
    - LI J; NY A; LEONARDSSON, G; NANDAKUMAR KS; HOLMDAHL R; NY T., "The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis", AM JPATHOL, (2005), vol. 166, pages 783 - 92
    - JUDEX MO; MUELLER BM, "Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more", AM JPATHOL, (2005), vol. 166, pages 645 - 647
    - LIJNEN HR., "Pleiotropic functions of plasminogen activator inhibitor-1.", J THROMB HAEMOST, (2005), vol. 1, pages 35 - 45
    - HILAL G; MARTEL-PELLETIER J; PELLETIER JP; RANGER P; LAJEUNESSE D., "Osteoblast-like cells from human subchondral osteoartbritic bone demonstrate analtered phenotype in vitro. Possible role in subchondral bone sclerosis", ARTHRITIS RHEUM, (1998), vol. 41, pages 891 - 899
    - RONDAY HK; SMITS HH; QUAX PH; VAN DER PLUIJM G; LOWIK CW; BREEDVELD FC; VERHEIJEN JH., "Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis", BRJRHEUMATOL, (1997), vol. 36, doi:doi:10.1093/rheumatology/36.1.9, pages 9 - 15, XP002246935

DOI:   http://dx.doi.org/10.1093/rheumatology/36.1.9
    - NOVAK JF; HAYES JD; NISHIMOTO SK., "mediated proteolysis of osteocalcin", J BONE MINER RES, (1997), vol. 12, pages 1035 - 1042
    - DACI E; UDAGAVA N; MARTIN TJ; BOUILLON R; CARMELIET G., "The role of the plasminogen system in bone resorption in vitro", JBONE MINER RES, (1999), vol. 14, pages 946 - 52
    - SAKAMAKI H; OGURA N; KUJIRAOKA H; AKIBA, M; ABIKAO Y; NAGURA H., "Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders", INT J ORAL MAXILLOFAC SURG, (2001), vol. 30, pages 323 - 328
    - ROY ME; NISHIMOTO SK., "Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity", BONE, (2002), vol. 31, pages 296 - 302
    - DACI E.; EVERTS V; TORREKENS S; VAN HERCK E; TIGCHELAAR-GUTTERR W; BOUILLON R; CARMELIET G., "Increased bone formation in mice lacking plasminogen activators", J MINERRES BONE, (2003), vol. 18, pages 1167 - 76
    - CHOONG PF; NADESAPILLAI., "Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis", CLIN ORTHOP RELAT RES, (2003), vol. 415, pages S46 - S58
    - CASTELLINO FJ; PLOPLIS VA., "Structure and function of the plasminogen/plasmin system", THROMB HAEMOST, (2005), vol. 93, pages 647 - 54
    - SPRECHER CA; KISIEL W; MATHEWES S; FOSTER DC., "Molecular cloning, expression, and partial characterization of a second human tissue factor pathway inhibitor", PROC ATLACA SCI USA, (1994), vol. 91, pages 3353 - 7
    - MIYAGI Y; KOSHIKAWA N; YASUMITSU H; MIYAGI E; HIRAHARA F; AOKI I; MISUGI K; UMEDA M; MIYAZAKI K., "cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2", JBIOCHEM (TOKYO, (1994), vol. 116, pages 939 - 42, XP000973739
    - RAO CN; PEAVEY CL; LIU YY; LAPIERE JC; WOODLEY DT., "Partial characterization of matrix-associated serine protease inhibitors from human skin cells", J INVEST. DERMATOL., (1995), vol. 104, doi:doi:10.1111/1523-1747.ep12665851, pages 379 - 383, XP000999611

DOI:   http://dx.doi.org/10.1111/1523-1747.ep12665851
    - UDAGAWA K; MIYAGI Y; HIRAHARA F; MIYAGI E; NAGASHIMA, Y; MINAGUCHI H; MISUGI K; YASUMITSU H; MIYAZAKI K., "Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization", PLACENTA, (1998), vol. 19, pages 217 - 223
    - SUGIYAMA T; ISHII S; YAMAMOTO J; IRIE R; SAITO K; OTUKI T; WAKAMATSU A; SUZUKI Y; HIO Y; OTA T, "cDNA macroarray analysis of gene expression in synoviocytes stimulated with TNFalpha", FEBS LETT., (2002), vol. 517, doi:doi:10.1016/S0014-5793(02)02588-7, pages 121 - 128, XP004350273

DOI:   http://dx.doi.org/10.1016/S0014-5793(02)02588-7
    - LINO M; FOSTER DC; KISIEL W, "Quantification and characterization of human endothelial cell-derived tissue factor pathway inbibitor-2", ARTERIOSCLER. THROMB. VASC. BIOL., (1998), vol. 18, pages 40 - 46
    - RAO CN; REDDY P; LIU YY; O'TOOLE EAO; REEDER DJ; FOSTER DC; KISIEL W; WOODLEY, DT., "Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2", ARCH. BIOCHEM. BIOPHYS, (1996), vol. 335, pages 45 - 52
    - CHAND, H. S.; SCHMIDT, A. E.; BAJAJ, S. P.; KISIEL, W., "Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inbibitor-2", JBIOL CHEM, (2004), vol. 279, pages 17500 - 17507
    - HUBER R; KUKLA D; BODE W; SCHWAGER P; BARTELS K; DEISENHOFER J; STEIGEMANN W., "Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor, n. Crystallographic refinement at 1.9 A resolution", JMOL BIOL., (1974), vol. 89, doi:doi:10.1016/0022-2836(74)90163-6, pages 73 - 101, XP024012039

DOI:   http://dx.doi.org/10.1016/0022-2836(74)90163-6
    - SCHMIDT AE; CHAND HS; CASCIO D; KISIEL W; BAJAJ SP., "Crystal Structure of Kunitz Domain 1 (KD1) of Tissue Factor Pathway Inhibitor-2 in Complex with Trypsin: Implications for KD1 Specificity of Inhibition", J IOL CHEM, (2005), vol. 280, pages 27832 - 27838
    - WANG, X.; LIN, X.; LOY, J. A.; TANG, J.; ZHANG, X. C., "Crystal structure of the catalytic domain of human plasmin complexed with streptokinase", SCIENCE, (1998), vol. 281, doi:doi:10.1126/science.281.5383.1662, pages 1662 - 1665, XP002113671

DOI:   http://dx.doi.org/10.1126/science.281.5383.1662
    - BAJAJ, M. S.; BIRKTOFT, J. J.; STEER, S. A.; BAJAJ, S. P., "Structure and biology of tissue factor pathway inhibitor", THROMB. HAEMOST., (2001), vol. 86, pages 959 - 972
    - BEIERLEIN W; SCHEULE AM; DIETRICH W; ZIEMER G., "Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions", ANN THORAC SURG., (2005), vol. 79, doi:doi:10.1016/j.athoracsur.2004.03.072, pages 741 - 748, XP026155826

DOI:   http://dx.doi.org/10.1016/j.athoracsur.2004.03.072
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.